<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema - Altmann, ES - 2019 | Cochrane Library</title> <meta content="Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema - Altmann, ES - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002312.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema - Altmann, ES - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002312.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002312.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema" name="citation_title"/> <meta content="Emile S Altmann" name="citation_author"/> <meta content="John Hunter Hospital" name="citation_author_institution"/> <meta content="Emile.Altmann@health.nsw.gov.au" name="citation_author_email"/> <meta content="Iain Crossingham" name="citation_author"/> <meta content="East Lancashire Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Stephen Wilson" name="citation_author"/> <meta content="East Lancashire Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Huw R Davies" name="citation_author"/> <meta content="Southern Adelaide Local Health Network (SALHN)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD002312.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002312.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002312.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002312.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Bacterial Agents [therapeutic use]; Drainage; Empyema, Pleural [*therapy]; Fibrinolytic Agents [*therapeutic use]; Pleural Effusion [*therapy]; Randomized Controlled Trials as Topic; Streptokinase [therapeutic use]; Thrombolytic Therapy [*methods]; Tissue Plasminogen Activator [therapeutic use]; Urokinase‐Type Plasminogen Activator [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002312.pub4&amp;doi=10.1002/14651858.CD002312.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002312\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002312\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002312.pub4",title:"Intra\\u2010pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema",firstPublishedDate:"Oct 30, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002312.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002312.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002312.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002312.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002312.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002312.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002312.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002312.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002312.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002312.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12499 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002312.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/appendices#CD002312-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/table_n/CD002312StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/table_n/CD002312StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information#CD002312-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Emile S Altmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information#CD002312-cr-0003">Iain Crossingham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information#CD002312-cr-0004">Stephen Wilson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information#CD002312-cr-0005">Huw R Davies</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information/en#CD002312-sec1-0016">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002312.pub4">https://doi.org/10.1002/14651858.CD002312.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002312-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002312-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002312-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002312-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002312-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002312-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002312-abs-0001" lang="en"> <section id="CD002312-abs1-0001"> <h3 class="title" id="CD002312-abs1-0001">Background</h3> <p>Pleural infection, including parapneumonic effusions and thoracic empyema, may complicate lower respiratory tract infections. Standard treatment of these collections in adults involves antibiotic therapy, effective drainage of infected fluid and surgical intervention if conservative management fails. Intrapleural fibrinolytic agents such as streptokinase and alteplase have been hypothesised to improve fluid drainage in complicated parapneumonic effusions and empyema and therefore improve treatment outcomes and prevent the need for thoracic surgical intervention. Intrapleural fibrinolytic agents have been used in combination with DNase, but this is beyond the scope of this review. </p> </section> <section id="CD002312-abs1-0002"> <h3 class="title" id="CD002312-abs1-0002">Objectives</h3> <p>To assess the benefits and harms of adding intrapleural fibrinolytic therapy to standard conservative therapy (intercostal catheter drainage and antibiotic therapy) in the treatment of complicated parapneumonic effusions and empyema. </p> </section> <section id="CD002312-abs1-0003"> <h3 class="title" id="CD002312-abs1-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase, ClinicalTrials.gov and the World Health Organization (WHO) trials portal. We contacted trial authors for further information and requested details regarding the possibility of unpublished trials. The most recent search was conducted on 28 August 2019. </p> </section> <section id="CD002312-abs1-0004"> <h3 class="title" id="CD002312-abs1-0004">Selection criteria</h3> <p>Parallel‐group randomised controlled trials (RCTs) in adult patients with post‐pneumonic empyema or complicated parapneumonic effusions (excluding tuberculous effusions) who had not had prior surgical intervention or trauma comparing an intrapleural fibrinolytic agent (streptokinase, alteplase or urokinase) versus placebo or a comparison of two fibrinolytic agents. </p> </section> <section id="CD002312-abs1-0005"> <h3 class="title" id="CD002312-abs1-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data. We contacted study authors for further information. We used odds ratios (OR) for dichotomous data and reported 95% confidence intervals (CIs). We used Cochrane's standard methodological procedures of meta‐analysis. We applied the GRADE approach to summarise results and to assess the overall certainty of evidence. </p> </section> <section id="CD002312-abs1-0006"> <h3 class="title" id="CD002312-abs1-0006">Main results</h3> <p>We included in this review a total of 12 RCTs. Ten studies assessed fibrinolytic agents versus placebo (993 participants); one study compared streptokinase with urokinase (50 participants); and one compared alteplase versus urokinase (99 participants). The primary outcomes were death, requirement for surgical intervention, overall treatment failure and serious adverse effects. All studies were in the inpatient setting. Outcomes were measured at varying time points from hospital discharge to three months. Seven trials were at low or unclear risk of bias and two at high risk of bias due to inadequate randomisation and inappropriate study design respectively. </p> <p>We found no evidence of difference in overall mortality with fibrinolytic versus placebo (OR 1.16, 95% CI 0.71 to 1.91; 8 studies, 867 participants; I² = 0%; moderate certainty of evidence). We found evidence of a reduction in surgical intervention with fibrinolysis in the same studies (OR 0.37, 95% CI 0.21 to 0.68; 8 studies, 897 participants; I² = 51%; low certainty of evidence); and overall treatment failure (OR 0.16, 95% CI 0.05 to 0.58; 7 studies, 769 participants; I² = 88%; very low certainty of evidence, with evidence of significant heterogeneity). We found no clear evidence of an increase in adverse effects with intrapleural fibrinolysis, although this cannot be excluded (OR 1.28, 95% CI 0.36 to 4.57; low certainty of evidence). In a sensitivity analysis, the reduction in referrals for surgery and overall treatment failure with fibrinolysis disappeared when the analysis was confined to studies at low or unclear risk of bias. In a moderate‐risk population (baseline 14% risk of death, 20% risk of surgery, 27% risk of treatment failure), intra‐pleural fibrinolysis leads to 19 more deaths (36 fewer to 59 more), 115 fewer surgical interventions (150 fewer to 55 fewer) and 214 fewer overall treatment failures (252 fewer to 93 fewer) per 1000 people. </p> <p>A single study of streptokinase versus urokinase found no clear difference between the treatments for requirement for surgery (OR 1.00, 95% CI 0.13 to 7.72; 50 participants; low‐certainty evidence). A single study of alteplase versus urokinase showed no clear difference in requirement for surgery (OR alteplase versus urokinase 0.46, 95% CI 0.04 to 5.24) but an increased rate of adverse effects, primarily bleeding, with alteplase (OR 5.61, 95% CI 1.16 to 27.11; 99 participants; low‐certainty evidence). This translated into 154 (6 to 499 more) serious adverse events with alteplase compared with urokinase per 1000 people treated. </p> </section> <section id="CD002312-abs1-0007"> <h3 class="title" id="CD002312-abs1-0007">Authors' conclusions</h3> <p>In patients with complicated infective pleural effusion or empyema, intrapleural fibrinolytic therapy was associated with a reduction in the requirement for surgical intervention and overall treatment failure but with no evidence of change in mortality. Discordance between the negative largest trial of this therapy and other studies is of concern, however, as is an absence of significant effect when analysing low risk of bias trials only. The reasons for this difference are uncertain but may include publication bias. Intrapleural fibrinolytics may increase the rate of serious adverse events, but the evidence is insufficient to confirm or exclude this possibility. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002312-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002312-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002312-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002312-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002312-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002312-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002312-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002312-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002312-abs-0006" lang="en"> <h3>Clot‐busting drugs for infections of the lining of the lung</h3> <p><b>Background</b> </p> <p>Empyema and complicated parapneumonic effusion are conditions involving infected fluid gathering between the lung and the chest wall (the pleural space). They are treated by draining the fluid with a tube inserted through the chest into the fluid (a 'chest tube'), along with antibiotics. If this does not work, then surgery is usually needed to drain the fluid. Fibrinolytic drugs ('clot‐busting drugs') may make the infected pleural fluid thinner, less sticky and easier to drain via a chest tube, meaning that surgery may not be needed. </p> <p><b>Review question</b> </p> <p>We wanted to know if fibrinolytics reduced the need for people with infections in the pleural space to have surgery to fix the infection. We also wanted to see if these medicines reduced the chance of people dying due to these infections; whether the fibrinolytic treatment worked overall; and whether these medicines caused serious side effects. We also wanted to know if one fibrinolytic medicine was more effective than another. </p> <p><b>Study characteristics</b> </p> <p>We searched for studies up to August 2019. We included 10 studies with a total of 993 patients comparing fibrinolytics with a placebo and compared these to look for differences. We also included two studies comparing different fibrinolytics with a total of 149 patients and compared these separately. </p> <p><b>Key findings</b> </p> <p>We found some low‐certainty evidence that fibrinolytics moderately reduced the need for surgery. There was no clear evidence that fibrinolytics changed the risk of death. There was some low‐certainty evidence which showed that there may be a risk of more side effects (mostly bleeding) with fibrinolytics but this is uncertain. We found no clear evidence that any single fibrinolytic was better than another. </p> <p><b>Certainty of the evidence</b> </p> <p>We considered the certainty of the evidence identified comparing fibrinolytic with placebo to vary from moderate (risk of death) to very low (overall treatment failure). This was mostly due to some studies having one or more domains at high risk of bias as well as concerns that not all studies of this treatment appear to have been published. We considered the evidence comparing individual fibrinolytics to be of low certainty due to not enough patients in the studies as well as one study being at a high risk of bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002312-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002312-sec1-0007"></div> <h3 class="title" id="CD002312-sec1-0008">Implications for practice</h3> <section id="CD002312-sec1-0008"> <p>Meta‐analysis of the trials included in this review has shown that intrapleural fibrinolytic therapy gave a reduction in requirement for surgical intervention compared to placebo although the certainty of the evidence which we have found is low. Furthermore, there was a reduction in overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy among participants receiving therapy rather than placebo with very low certainty. We identified no clear change to mortality alone (moderate‐certainty evidence). There is discordance between the largest trial (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>) and the overall result. The reasons for this are uncertain but may include publication bias, of which we are suspicious. </p> <p>Intrapleural fibrinolysis may be a reasonable therapy in patients with empyema or complex parapneumonic effusion, particularly in patients in whom surgery is contraindicated. The trials included do suggest a possible increase in serious adverse effects with fibrinolysis (low‐certainty evidence). </p> </section> <h3 class="title" id="CD002312-sec1-0009">Implications for research</h3> <section id="CD002312-sec1-0009"> <p>Although we did not consider combined fibrinolytic/DNase therapy in this review, it may be appropriate to consider for an update or a separate systematic review. Any further trials of intrapleural fibrinolysis (with or without DNase) should replicate as closely as possible the demographics of the empyema/complex parapneumonic effusion population with regards to age and comorbidity. Major outcomes should be direct and patient centred (e.g. death, requirement for surgery and serious adverse events) rather than proxy outcomes such as clearance of pleural fluid. We would discourage intermediate fibrinolysis steps or cross‐over studies such as in <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a> and <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>. Additionally, more data is required regarding serious adverse events as there is uncertainty if fibrinolytic therapy is associated with morbidity and current treatment numbers are insufficient to make a determination. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002312-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002312-sec1-0001"></div> <div class="table" id="CD002312-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fibrinolytics compared to placebo in the treatment of complicated parapneumonic effusions and empyema</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fibrinolytics compared to placebo in the treatment of complicated parapneumonic effusions and empyema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult parapneumonic effusions and empyema<br/> <b>Setting:</b> hospital inpatients<br/> <b>Intervention:</b> fibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality.</p> <p>Follow‐up: range 3 months to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.16<br/> (0.71 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>867<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fibrinolysis does not dramatically alter the risk of death. The confidence intervals are wide so we cannot exclude a modest increase in mortality with fibrinolytics. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/> (104 to 235) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Referral for thoracic surgery.<br/> Follow‐up: range 3 months to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>OR 0.37<br/> (0.21 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>897<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Fibrinolytics probably reduce the rate of surgical intervention for empyema, though the use of surgery varies substantially between centres. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (11 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (50 to 145) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000<br/> (174 to 405) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy.<br/> Follow‐up: range 3 months to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.16<br/> (0.05 to 0.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>769<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fibrinolysis may reduce overall treatment failure, perhaps by reducing need for surgical intervention. This result is potentially unreliable as the effect is not seen once the analysis is confined to studies of low risk of bias. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (18 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.28<br/> (0.36 to 4.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>935<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>8 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Given the broad confidence intervals, we cannot exclude a modest increase in treatment complications (particularly bleeding) with fibrinolysis </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/> (23 to 106) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> 14% Mortality rate taken from the placebo arm of the largest study (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>). </p> <p><sup>2</sup> Downgraded by 1 point as 4 of the included studies were deemed at high risk of bias in at least 1 domain. </p> <p><sup>3</sup> Downgraded by 1 point as funnel plots (<a href="./full#CD002312-fig-0001">Figure 1</a>, <a href="./full#CD002312-fig-0002">Figure 2</a>) suggests significant risk of publication bias. </p> <p><sup>4</sup> Decision to operate is dependent on many local factors. Example low, moderate and high surgical risk chosen are consistent with the range seen in included trials and authors' practice. </p> <p><sup>5</sup> Downgraded by 1 point as there is inconsistency between <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> (the largest study, deemed at low risk of bias) and many of the other studies. </p> <p><sup>6</sup> 27% placebo failure rate taken from <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>. </p> <p><sup>7</sup> 3% significant complication rate taken from placebo arm of <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>. </p> <p><sup>8</sup> Downgraded by 1 point as 5 of the included studies were deemed at high risk of bias in at least 1 domain. </p> <p><sup>9</sup> Broad confidence intervals do not rule out a clinically significant increase in treatment complications with fibrinolytics so downgraded 1 point for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD002312-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.2 Referral for thoracic surgery (open or thorascopic)." data-id="CD002312-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.2 Referral for thoracic surgery (open or thorascopic). </p> </div> </div> </div> <div class="figure" id="CD002312-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy." data-id="CD002312-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy. </p> </div> </div> </div> <div class="table" id="CD002312-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Streptokinase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Streptokinase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult parapneumonic effusions and empyema<br/> <b>Setting:</b> hospital inpatients<br/> <b>Intervention:</b> streptokinase<br/> <b>Comparison:</b> urokinase </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with urokinase</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with streptokinase</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.32<br/> (0.01 to 8.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a single death in the urokinase group which was felt by the study authors to be unrelated to pleural infection. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (0 to 256) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Referral for thoracic surgery (open or thorascopic)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.13 to 7.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (11 to 402) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.13 to 7.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (11 to 402) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 5.43<br/> (0.25 to 118.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Based on 1 small RCT, not otherwise felt to be at high risk of bias. Downgraded 2 points for imprecision as very few events so very broad confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002312-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Alteplase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Alteplase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult parapneumonic effusions and empyema<br/> <b>Setting:</b> hospital inpatients<br/> <b>Intervention:</b> alteplase<br/> <b>Comparison:</b> urokinase </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with urokinase</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with alteplase</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.94<br/> (0.18 to 4.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/> (12 to 246) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Referral for thoracic surgery (open or thorascopic)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.46<br/> (0.04 to 5.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (2 to 186) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.02<br/> (0.89 to 10.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000<br/> (75 to 483) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 5.61<br/> (1.16 to 27.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Substantially more adverse events in the alteplase group compared with urokinase.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/> (48 to 541) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 point as based on 1 small RCT judged at high risk of bias in several domains. Also downgraded 1 point for imprecision ‐ wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002312-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002312-sec1-0002"></div> <section id="CD002312-sec2-0001"> <h3 class="title" id="CD002312-sec2-0001">Description of the condition</h3> <p>Thoracic empyema is defined as pus within the pleural space and is usually due to bacterial infection. Empyema may arise in association with pneumonia, as a result of a parapneumonic effusion (a type of pleural effusion, or build‐up of liquid, that arises as a result of a pneumonia) and this may progress from simple to complicated parapneumonic effusion (CPE). Alternately, it may present as a primary pleural infection (i.e. without evidence of pneumonia). </p> <p>Parapneumonic effusion may occur in up to 57% of pneumonia cases in adults (<a href="./references#CD002312-bbs2-0065" title="SahnSA . Management of complicated parapneumonic effusions. American Review of Respiratory Disease1993;148(3):813‐7. ">Sahn 1993</a>), progressing to empyema in 5% to 10% of people (<a href="./references#CD002312-bbs2-0069" title="StrangeC , SahnSA . The definitions and epidemiology of pleural space infection. Seminars in Respiratory Infections1999;14(1):3‐8. [PUBMED: 10197392] ">Strange 1999</a>). Mortality rates in empyema are approximately 20% overall (<a href="./references#CD002312-bbs2-0052" title="FarjahF , SymonsRG , KrishnadasanB , WoodDE , FlumDR . Management of pleural space infections: a population‐based analysis. Journal of Thoracic and Cardiovascular Surgery2007;133(2):346‐51. ">Farjah 2007</a>; <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>). The incidence of pleural infection has increased markedly in adults aged over 65 years (<a href="./references#CD002312-bbs2-0054" title="GrijalvaCG , ZhuY , NuortiJP , GriffinMR . Emergence of parapneumonic empyema in the USA. Thorax2011;66(8):663‐8. ">Grijalva 2011</a>), with a mortality rate greater than 30% in this population (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>). </p> <p>A parapneumonic effusion may constitute an incidental, non‐significant finding or become large and persistent. The formation of parapneumonic effusions can be divided into three stages (<a href="./references#CD002312-bbs2-0060" title="LightRW . Parapneumonic effusion and empyema. Clinical Chest Medicine1985;6(1):55‐62. ">Light 1985</a>; <a href="./references#CD002312-bbs2-0065" title="SahnSA . Management of complicated parapneumonic effusions. American Review of Respiratory Disease1993;148(3):813‐7. ">Sahn 1993</a>). Simple exudates with no loculations and pH greater than 7.2 do not necessarily require drainage. Fibrino‐purulent pleural fluid (with loculations or a pH less than 7.2) should, however, be drained as should organised empyema (<a href="./references#CD002312-bbs2-0051" title="DaviesHE , DaviesRJO , DaviesCWH . Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010. Thorax2010;65(Suppl 2):ii41‐ii53. ">Davies 2010</a>). </p> <p>Current guidelines from the American Association of Thoracic Surgeons (<a href="./references#CD002312-bbs2-0067" title="ShenKR , BribiescoA , CrabtreeT , DenlingerC , EbyJ , Eiken , P , et al. The American Association of Thoracic Surgery consensus guidelines for the management of empyema. Journal of Thoracic and Cardiovascular Surgery2017;153(6):e129‐e146. ">Shen 2017</a>) and from the British Thoracic Society (<a href="./references#CD002312-bbs2-0051" title="DaviesHE , DaviesRJO , DaviesCWH . Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010. Thorax2010;65(Suppl 2):ii41‐ii53. ">Davies 2010</a>) recommend that if chest tube drainage is ineffective then surgical procedures via video‐assisted thoracoscopic surgery (VATS) or thoracotomy should be first‐line management for empyema and CPE. Both guidelines recommend that intrapleural fibrinolysis not be routinely used<b>.</b> </p> </section> <section id="CD002312-sec2-0002"> <h3 class="title" id="CD002312-sec2-0002">Description of the intervention</h3> <p>For parapneumonic effusions which require clearance, appropriate therapy is effective drainage via an intercostal catheter (ICC) with antibiotic therapy. Frequently, simple ICC drainage is not effective due to the presence of loculations, formed predominantly by fibrinous material deposited in the fibrinopurulent phase of empyema, which prevent free drainage of infected pleural fluid (<a href="./references#CD002312-bbs2-0059" title="LeMensePG , StrangeC , SahnSA . Empyema thoracis. Therapeutic management and outcome. Chest1995;107(6):1532‐7. ">LeMense 1995</a>). The presence of fibrinous septae in the pleural space, known as loculations, may result in inadequate drainage of effusions and therefore non‐resolution of infection and systemic sepsis. Without effective intercostal catheter drainage, surgical intervention (VATS or open) has usually been required to clear loculations for resolution of infection. </p> <p>Non‐surgical treatment options to reduce the impact of adhesions and loculae include (in addition to appropriate antibiotic therapy) single and multiple thoracocenteses, or single and multiple intercostal tube thoracostomies, with or without intrapleural fibrinolytic agents. Surgical options include direct‐vision and VATS adhesiolysis, limited and full thoracotomy with adhesiolysis, and decortication for severe pleural thickening. </p> <p>Although the success rate of surgical intervention remains high (<a href="./references#CD002312-bbs2-0066" title="ScarciaM , AbahaU , PiergiorgioS , PageaA , WallerbD , vanSchilcP , et al. EACTS expert consensus statement for surgical management of pleural empyema. European Journal of Cardiothoracic Surgery2015;48(5):642‐53. ">Scarcia 2015</a>), the morbidity and mortality of both VATS and open thoracotomy are of concern, particularly in a cohort of patients who may be older and with significant co‐morbidity. Less invasive therapies which promote pleural space drainage and effective resolution of pleural infection are therefore likely to be of considerable clinical utility. </p> <p>Intra‐pleural chemical fibrinolysis in the management of complex parapneumonic effusions and thoracic empyema has been employed for over 50 years, with a mixture of agents including streptokinase/streptodornase (<a href="./references#CD002312-bbs2-0072" title="TillettWS , SherryS , ReadCT . The use of streptokinase‐streptodornase in the treatment of post‐pneumonic empyema. Journal of Thoracic Surgery1951;21(3):275‐97. ">Tillett 1951</a>), streptokinase (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>), urokinase (<a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>), alteplase (<a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>), and a combination of streptodornase and alteplase (<a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>). These medications are administered into the pleural space via an ICC. </p> </section> <section id="CD002312-sec2-0003"> <h3 class="title" id="CD002312-sec2-0003">How the intervention might work</h3> <p>Fibrinolytic agents including streptokinase, urokinase, alteplase and recombinant tissue plasminogen activator (rTPA) have been used safely and effectively intrapleurally for CPE and empyema (<a href="./references#CD002312-bbs2-0057" title="IdellS . Update on the use of fibrinolysins in pleural disease. Clinical Pulmonary Medicine2005;12(3):184‐90. ">Idell 2005</a>; <a href="./references#CD002312-bbs2-0045" title="SkeeteDA , RutherfordEJ , SchlidtSA , AbramsJE , ParkerLA , RichPB . Intrapleural tissue plasminogen activator for complicated pleural effusions. Journal of Trauma2004;57(6):1178‐83. ">Skeete 2004</a>; <a href="./references#CD002312-bbs2-0070" title="ThommiG , ShehanC , BellA , CoughlinN , McLeayM . Intrapleural instillation of TPA in the management of complicated pleural effusions. Chest2000;118(Suppl 4):S164. ">Thommi 2000</a>; <a href="./references#CD002312-bbs2-0073" title="WalkerCA , ShirkiMB , MarvaMT , ViscontiJ . Intrapleural alteplase in a patient with complicated pleural effusion. Annals of Pharmacotherapy2003;37(3):376‐9. ">Walker 2003</a>). During the fibrinopurulent‐purulent stage of empyema, there is an imbalance between fibrin activators and fibrin inhibitors (<a href="./references#CD002312-bbs2-0056" title="IdellS , GirardW , KoenigKB , McLartyJ , FairDS . Abnormalities of pathways of fibrin turnover in the human pleural space. American Review of Respiratory Disease1991;144(1):187‐94. ">Idell 1991</a>), with elevated levels of plasminogen activator inhibitor (PAI‐1) resulting from the presence of inflammation‐induced tumour necrosis factor‐alpha, interleukin 8 and transforming growth factor beta, as well as lower levels of endogenous tissue plasminogen activator (TPA) (<a href="./references#CD002312-bbs2-0050" title="ChungCL , ChenCH , SheuJR , ChenYC , ChuangSC . Proinflammatory cytokines, transforming growth factor‐beta1, and fibrinolytic enzymes in loculated and free‐flowing pleural exudates. Chest2005;128(2):690‐7. ">Chung 2005</a>). This results in a pro‐fibrotic state causing deposition of fibrin‐forming loculations within the infected pleural space (<a href="./references#CD002312-bbs2-0063" title="PiccoloF , PopowiczN , WongD , LeeYCG . Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. Journal of Thoracic Diseases2015;7(6):999‐1008. ">Piccolo 2015</a>). Fibrinolytic agents activate plasmin, lysing fibrinous septations, thereby improving pleural fluid drainage and clearing infection without requiring surgical intervention. Two deoxyribonucleases (DNase) have been used in pleural infection: dornase alfa is a highly purified recombinant human DNase, licensed for usage as a mucolytic (<a href="./references#CD002312-bbs2-0063" title="PiccoloF , PopowiczN , WongD , LeeYCG . Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. Journal of Thoracic Diseases2015;7(6):999‐1008. ">Piccolo 2015</a>); while streptodornase was used in earlier reports (<a href="./references#CD002312-bbs2-0072" title="TillettWS , SherryS , ReadCT . The use of streptokinase‐streptodornase in the treatment of post‐pneumonic empyema. Journal of Thoracic Surgery1951;21(3):275‐97. ">Tillett 1951</a>). Assessing DNase is beyond the scope of this review. </p> <p>Pus contains large amounts of deoxyribonucleoprotein content from leucocyte degradation which contributes significantly to pus viscosity. DNases in combination with a fibrinolytic agent breaks down this material thereby decreasing its viscosity. The combination of a fibrinolytic and a DNase has been shown to be more effective than either agent alone in a rabbit model (<a href="./references#CD002312-bbs2-0061" title="LightRW , NguyenT , MulliganME , SasseSA . The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung2000;178(1):13‐8. ">Light 2000</a>). The sole human randomised trial of this combined therapy also showed better pleural fluid clearance and reduced requirement for surgery (<a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>). </p> </section> <section id="CD002312-sec2-0004"> <h3 class="title" id="CD002312-sec2-0004">Why it is important to do this review</h3> <p>Given the usual alternative therapy of surgical intervention, and a patient group which is frequently older (<a href="./references#CD002312-bbs2-0054" title="GrijalvaCG , ZhuY , NuortiJP , GriffinMR . Emergence of parapneumonic empyema in the USA. Thorax2011;66(8):663‐8. ">Grijalva 2011</a>), multi‐morbid and which may not tolerate surgery well, there is clinical equipoise in the usage of intrapleural fibrinolysis as a treatment modality in pleural infection to improve outcomes and reduce requirements for surgery. This review updates a previous Cochrane Review (<a href="./references#CD002312-bbs2-0076" title="CameronR , DaviesHR . Intra‐pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database of Systematic Reviews2008;16(2):CD002312. ">Cameron 2008</a>) </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002312-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002312-sec1-0003"></div> <p>To assess the benefits and harms of adding intrapleural fibrinolytic therapy to standard conservative therapy (intercostal catheter drainage and antibiotic therapy) in the treatment of complicated parapneumonic effusions and empyema. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002312-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002312-sec1-0004"></div> <section id="CD002312-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002312-sec3-0001"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials.</p> </section> <section id="CD002312-sec3-0002"> <h4 class="title">Types of participants</h4> <p>We included trials with participants older than 14 years presenting with either thoracic empyema or complicated parapneumonic effusions. We excluded studies on known tuberculous effusions and those on participants with malignancy, trauma or prior surgical intervention. We also excluded trials comparing fibrinolytic therapy with surgical therapies. </p> </section> <section id="CD002312-sec3-0003"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD002312-lst1-0001"> <li> <p>Intrapleural fibrinolytics versus control</p> <ol id="CD002312-lst2-0001"> <li> <p>Intrapleural streptokinase versus intrapleural normal saline</p> </li> <li> <p>Intrapleural urokinase versus intrapleural normal saline</p> </li> <li> <p>Intrapleural alteplase versus intrapleural normal saline</p> </li> </ol> </li> <li> <p>Intrapleural streptokinase versus intrapleural urokinase</p> </li> <li> <p>Intrapleural alteplase versus intrapleural urokinase</p> </li> </ol> </p> </section> <section id="CD002312-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <section id="CD002312-sec4-0001"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002312-lst1-0002"> <li> <p>Mortality</p> </li> <li> <p>Referral for thoracic surgery (open or thorascopic)</p> </li> <li> <p>Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </p> </li> <li> <p>Serious adverse events</p> </li> </ol> </p> </section> <section id="CD002312-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p>None</p> </section> </section> </section> <section id="CD002312-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002312-sec3-0005"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Airways Information Specialist conducted searches in the following databases and trials registries. </p> <p> <ul id="CD002312-lst1-0003"> <li> <p>Cochrane Airways Register via the Cochrane Register of Studies (CRS Web) (searched 28 August 2019); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2010, Issue 8) via the Cochrane Register of Studies (CRS Web) (searched 28 August 2019); </p> </li> <li> <p>MEDLINE (Ovid) 1946 to December week 4 2017 (searched 28 August 2019);</p> </li> <li> <p>Embase (Ovid) 1976 to week 2 2018 (searched 28 August 2019);</p> </li> <li> <p>ClinicalTrials.gov (searched 28 August 2019);</p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (searched 28 August 2019). </p> </li> </ul> </p> <p>The full search strategies are detailed in <a href="./appendices#CD002312-sec2-0015">Appendix 1</a>. We searched databases from their inception to the present, with no restriction on language of publication, or publication type. We handsearched conference abstracts via the CENTRAL database. We searched ClinicalTrials.gov and the WHO trials portal for ongoing or unpublished trials. </p> </section> <section id="CD002312-sec3-0006"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of all primary studies and review articles for additional references. We contacted authors of identified trials and asked them to identify other published and unpublished studies. </p> </section> </section> <section id="CD002312-sec2-0007"> <h3 class="title" id="CD002312-sec2-0007">Data collection and analysis</h3> <section id="CD002312-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>EA and IC independently reviewed titles and abstracts to identify all potential RCTs and obtained full‐text versions of these articles. . We reviewed online supplementary data where available. Cochrane language specialists reviewed studies in languages other than English for consideration of inclusion. </p> </section> <section id="CD002312-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>We extracted data for all included studies using Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) and standard templates and methods. Two out of three authors (EA, IC and SW), working independently, updated 'Risk of bias' assessments for all included studies in line with current Cochrane protocols. </p> </section> <section id="CD002312-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002312-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreements by discussion. We assessed risk of bias according to the following domains. </p> <p> <ol id="CD002312-lst1-0004"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear and provide a quote from the study report together with a justification for the judgment in the 'Risk of bias' table. We have summarised the 'Risk of bias' judgements across different studies for each of the domains listed in <a href="#CD002312-fig-0003">Figure 3</a>. We have noted in the 'Risk of bias' table where information on risk of bias relates to unpublished data or correspondence with a trialist. </p> <div class="figure" id="CD002312-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002312-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD002312-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>We assessed trial outcomes for comparability. We analysed dichotomous outcomes as odds ratios with 95% confidence intervals. We analysed all data using Review Manager 5 software (<a href="./references#CD002312-bbs2-0064" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD002312-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <p>Individual patients were used as the unit of analysis in all cases.</p> </section> <section id="CD002312-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>We assumed that loss of participants before baseline measurements were obtained had no effect on the eventual outcome data of the study. We analysed remaining studies on an intention‐to‐treat analysis. Where missing data was necessary for study inclusion, we made contact with authors and data were provided in private communication. </p> </section> <section id="CD002312-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. We reported if we identified greater than moderate heterogeneity (I² &gt; 30%). </p> </section> <section id="CD002312-sec3-0014"> <h4 class="title">Assessment of reporting biases</h4> <p>We visually inspected funnel plots for evidence of reporting bias.</p> </section> <section id="CD002312-sec3-0015"> <h4 class="title">Data synthesis</h4> <p>We used random‐effects models to obtain summary statistics for the overall efficacy and safety of fibrinolytics on the studied outcomes. </p> <section id="CD002312-sec4-0003"> <h5 class="title">'Summary of findings' table</h5> <p>We created 'Summary of findings' tables using the following outcomes: death; referral for surgical intervention; overall treatment failure; adverse events<i>.</i> We used the five GRADE considerations (study limitations; consistency of effect; imprecision; indirectness; and publication bias) to assess the certainty of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> using GRADEpro software (<a href="./references#CD002312-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD002312-bbs2-0053" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed before 18 September 2019). ">GRADEpro GDT</a>). We have justified all decisions to downgrade the certainty of evidence in footnotes below the tables. </p> </section> </section> <section id="CD002312-sec3-0016"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity amongst the trials for each outcome.</p> </section> <section id="CD002312-sec3-0017"> <h4 class="title">Sensitivity analysis</h4> <p>Outcomes are presented with data from all studies, from those studies at 'low risk of bias', or 'low or unclear risk of bias' and those at 'high risk of bias' (in one or more domains). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002312-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002312-sec1-0005"></div> <section id="CD002312-sec2-0008"> <h3 class="title">Description of studies</h3> <section id="CD002312-sec3-0018"> <h4 class="title">Results of the search</h4> <p>The last update of the review included a search run in 2008 (<a href="./references#CD002312-bbs2-0076" title="CameronR , DaviesHR . Intra‐pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database of Systematic Reviews2008;16(2):CD002312. ">Cameron 2008</a>). Update searches conducted in August 2019 identified 528 references. Following exclusion on the basis of abstracts and the identification of duplicate references, we retrieved 45 studies for full‐text scrutiny. We included five new studies from the search plus seven from the previous update (see <a href="#CD002312-fig-0004">Figure 4</a> for study flow diagram). </p> <div class="figure" id="CD002312-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Study flow diagram for 2019 update." data-id="CD002312-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for 2019 update.</p> </div> </div> </div> </section> <section id="CD002312-sec3-0019"> <h4 class="title">Included studies</h4> <p>A total of 12 RCTs met the inclusion criteria of the review. Eight English language full article studies (<a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>; <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>; <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>; <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>), one English language abstract only publication (<a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a>), and one Chinese language full article (<a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>) compare intrapleural fibrinolytic with normal saline control in a combined total of 993 participants. This includes one English language article comparing intrapleural fibrinolytics (alteplase) with a DNase (streptodornase alfa) and placebo in a 2 × 2 factorial manner (<a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>). However we only used data from the altepase versus placebo comparison in this review. </p> <p>One English language full article directly compared streptokinase with urokinase (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>). One English language full article directly compared alteplase with urokinase (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>). </p> <p>Details of each study including eligibility criteria and treatment regimens are given in the table '<a href="./references#CD002312-sec2-0019" title="">Characteristics of included studies</a>'. </p> <section id="CD002312-sec4-0004"> <h5 class="title">Study design</h5> <p>All 12 studies were RCTs. Blinding was undertaken in all trials. <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a> had a treatment algorithm where all patients who failed conservative treatment were given fibrinolysis before consideration for surgery. Referral for fibrinolysis in this group was therefore considered an overall treatment failure but only patients who were referred for surgery following the cross‐over therapy were considered surgical referrals. <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> crossed over patients from the placebo to alteplase groups or vice versa if they failed placebo or alteplase treatment respectively: crossing over to fibrinolytic therapy in this study was therefore considered an overall treatment failure but not a surgical referral and the outcome of the cross‐over treatment in this study was not considered for the purpose of this review. <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> was a 2 × 2 factorial trial, and we used only data from the relevant groups (i.e. alteplase and placebo groups); <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> was therefore treated as standard RCT for the purposes of this review. </p> </section> <section id="CD002312-sec4-0005"> <h5 class="title">Participants</h5> <p>The age range of participants was from 15 to 92 years. Participants were recruited in hospital having presented with parapneumonic effusion only in six studies (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>; <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>; <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>), and with parapneumonic effusions and empyema in six studies (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>; <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a>; <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>). Significant comorbidity was common amongst participants, with rates of comorbidity of 38% in <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>, more than 50% of cases in <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>, 74% of participants in <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> and 62% in <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>. <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> and <a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a> provide data on individual comorbidities which appear to be comparable to other studies but do not provide an overall rate of comorbidity. <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>, <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>, <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a> and <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a> do not provide information on underlying patient co‐morbidity, </p> </section> <section id="CD002312-sec4-0006"> <h5 class="title">Interventions</h5> <p>Ten of the studies compared fibrinolytic therapy with saline only; one trial compared fibrinolytic therapy and DNase in a 2 × 2 factorial manner (<a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>); one trial compared streptokinase with urokinase (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>); and one compared alteplase with urokinase (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>). Full details of which fibrinolytic therapy, dose and delivery mechanism are given in the table '<a href="./references#CD002312-sec2-0019" title="">Characteristics of included studies</a>'. There was some variation between study durations, with <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a> and <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a> assessing outcome at the end of hospital stay whereas eight studies followed up participants beyond hospital discharge (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>; <a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>; <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>; <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>). Time points of assessment were unclear in <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a> and <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>. Where data from multiple time points of mortality or requirement for surgical intervention were available, we have taken data from the time point closest to three months following administration of fibrinolytic therapy. </p> </section> <section id="CD002312-sec4-0007"> <h5 class="title">Outcomes</h5> <p>The outcomes of treatment failure resulting in death or referral for surgery were available in seven of the studies assessing fibrinolytics in comparison with placebo (<a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>; <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>; <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>); in the one trial assessing alteplase and urokinase (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>); and in the one trial assessing streptokinase and urokinase (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>). Eight studies had data for referral for surgery (<a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>, <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>, <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>, <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>, <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>, <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a>, <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> and <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>). One study had neither an overall treatment failure, referral for surgery or death outcome (<a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>). The outcome of death was available in 10 of the studies (unavailable in <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a> and <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>). </p> <p>In one study, failure of treatment in the saline arm resulted in a subsequent trial of intrapleural fibrinolytic before surgical intervention was considered (<a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>). The need for fibrinolytic therapy in this instance was regarded as a treatment failure. One study crossed over patients who had less than 50% reduction in CT fluid volume to the other group (<a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>). This study had a number of intermediate dropouts between treatments. In this case, group cross‐over was regarded as treatment failure and cross‐over treatment success was not used in this review. </p> </section> </section> <section id="CD002312-sec3-0020"> <h4 class="title">Excluded studies</h4> <p>We excluded 25 studies with reasons: see <a href="./references#CD002312-sec2-0020" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD002312-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias judgements and the information on which they are predicated are provided in <a href="./references#CD002312-sec2-0019" title="">Characteristics of included studies</a>. Overall two of the 12 studies were at low overall risk of bias with no items at unclear or high risk of bias (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>; <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>); three were at unclear risk of bias with no items at high risk of bias (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>); and seven were at high risk of bias (<a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>; <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a>; <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>; <a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>). </p> <section id="CD002312-sec3-0021"> <h4 class="title">Allocation</h4> <p>Following correspondence with the study investigators we were able to confirm appropriate generation of randomisation sequence (for example by a computer‐generated system) for six studies (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>). <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> was the only study to use minimisation in addition to random sequence generation. <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> reported that randomisation occurred centrally. <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a> did not report the method of randomisation, but allocation was concealed with opaque envelopes. <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a> reported that allocation was performed on the basis of hospital number (odd/even): this is inadequate concealment and we considered that it placed the study at high risk of bias for allocation. <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a> and <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a> provided no information on sequence generation. <a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a> allocated using a stratified randomised number table technique which has an unclear risk of selection bias. </p> <p>Allocation concealment was low risk and adequately described in <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> and <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> via central telephone allocation. <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a> described a single author not involved in clinical care as the sole holder of allocation, which we thought to be low risk. <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a> described adequate blinded opaque envelope allocation in private communication. <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> had a pharmacist not involved in clinical care holding allocation. No information was available regarding allocation concealment for five studies (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>; <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a>). We considered <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a> to be at high risk of allocation concealment bias due to the hospital‐number‐based method of allocation. </p> </section> <section id="CD002312-sec3-0022"> <h4 class="title">Blinding</h4> <p>There was a low risk of bias due to participant and treating team blinding (including data from private communication) in eight of the included trials. No information was available for <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a> and <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a>. <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a> was explicitly non‐blinded to the surgical team and therefore at high risk of bias. In <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a> nursing staff preparing study drugs for administration were unblinded, placing this study at high risk of bias. </p> <p>There was a low risk of bias due to blinding of outcome assessor in eight studies (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a>; <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>; <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>; <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>; <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>). No information was available for <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a> or <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>. <a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a> broke blinding mid‐way through the trial due to a valid concern of an excess of adverse events (major bleeding) in the alteplase 20 mg arm, putting this study at high risk of bias. We considered <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a> to be at high risk of bias, with concerns that not all treating staff were blinded. </p> </section> <section id="CD002312-sec3-0023"> <h4 class="title">Incomplete outcome data</h4> <p>Studies reporting no withdrawals were <a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997,</a><a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997,</a><a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999,</a> and <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>. No information regarding attrition was available for <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a> and <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a>. Intention‐to‐treat analyses were reported for <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a> and <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>. <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> analysed data with a modified intention‐to‐treat analysis, with exclusion of six patients who did not receive study medication and 11 who had less than 5% of fluid‐occupied hemithorax at baseline. <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a> analysed data from those who completed the study. In this study there was a significantly higher dropout rate in the intervention arm (8/65) compared with the control arm (0/70), putting the study at high risk of bias for incomplete outcome data. <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> had a high number of post‐randomisation withdrawals for varied reasons, placing the study at high risk of bias. <a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a> had a higher rate of withdrawal in the alteplase arms, particularly the 20 mg arm due to adverse events (predominantly bleeding), placing the study at a higher risk of bias. </p> </section> <section id="CD002312-sec3-0024"> <h4 class="title">Selective reporting</h4> <p>Full study protocols were only available for <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> and <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>. Review of these protocols confirmed that all proposed outcomes (and no additional post hoc results) were reported, placing these studies at low risk of selective reporting. Six studies did not have available protocols; however these studies reported all outcomes documented in the methods of each publication and we have therefore taken these to be at low risk of selective reporting (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a>; <a href="./references#CD002312-bbs2-0008" title="MisthosP , SepsasE , KonstantinouM , AthanassiadiK , SkottisI , LiouliasA . Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery2005;28(4):599‐603. ">Misthos 2005</a>; <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>). Although <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> reported significant variation between planned primary outcome (reduction in surgical intervention between alteplase and placebo groups) and the reported primary outcome, which was proportion of patients with at least 50% reduction in pleural fluid volume on radiologic examination, this did not affect the extracted data as we took data from the cross‐over point of this study. <a href="./references#CD002312-bbs2-0009" title="PrasadBNBM , BhattacharyyaD , LuthraM , MathurAD . Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2009;179:A4486 [Poster #G115]. ">Prasad 2009</a> reported a single outcome (requirement for surgery) in abstract form only. Given a full report would have been likely to be published in a longer form, we believe this places this study at high risk of selective reporting bias. </p> </section> <section id="CD002312-sec3-0025"> <h4 class="title">Other potential sources of bias</h4> <p>We considered <a href="./references#CD002312-bbs2-0006" title="LinJ‐C , ZhangC‐R , LiM , ZhouH , NiuY‐Y , LiuX‐Y . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians2011;5(9):2610‐14. LinJ‐C , ZhangC‐R , XuW‐M , LiM , CuiW‐L . Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases2011;15(suppl 1):S104‐5. ">Lin 2011</a> to be at high risk of bias due to the absence of a number of usual outcome measures (death, referral for surgery, treatment failure) which would have been reported in the vast majority of studies. <a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a> deliberately broke blinding after a number of excess adverse events in the alteplase 20 mg arm, which required a mid‐trial protocol change, placing the study at a high risk of bias. <a href="./references#CD002312-bbs2-0005" title="DiaconAH , TheronJ , SchuurmansMM , Van deWalBW , BolligerCT . Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine2004;170(1):49‐53. ">Diacon 2004</a> had a significant (6/53) number of post‐randomisation exclusions, placing it at high risk of bias. </p> </section> </section> <section id="CD002312-sec2-0010"> <h3 class="title" id="CD002312-sec2-0010">Effects of interventions</h3> <p>See: <a href="./full#CD002312-tbl-0001"><b>Summary of findings for the main comparison</b> Fibrinolytics compared to placebo in the treatment of complicated parapneumonic effusions and empyema</a>; <a href="./full#CD002312-tbl-0002"><b>Summary of findings 2</b> Streptokinase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</a>; <a href="./full#CD002312-tbl-0003"><b>Summary of findings 3</b> Alteplase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</a> </p> <p>We performed analysis of studies for the outcomes of mortality, referral for thoracic surgery (open or thorascopic) and overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy and occurrence of serious adverse events. For two studies, an intermediate fibrinolysis step took place prior to referral for surgery for patients administered placebo who experienced treatment failure (<a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>). For these studies, we have determined that a patient being referred for intermediate fibrinolysis was an overall treatment failure but only patients who subsequently were referred for surgery after an intermediate fibrinolysis step were counted as referrals for surgery. </p> <p>We present below the findings by comparison, outcome and then by sensitivity analysis, with removal of studies at high risk of bias. </p> <section id="CD002312-sec3-0026"> <h4 class="title">Fibrinolytic therapy versus placebo (loculation and empyema)</h4> <section id="CD002312-sec4-0008"> <h5 class="title">Mortality</h5> <p>Eight studies of fibrinolytics versus placebo reported death as an outcome, although there were no deaths in either group in four of the studies (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>; <a href="./references#CD002312-bbs2-0004" title="DaviesRJ , TraillZC , GleesonFV . Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax1997;52(5):416‐21. ">Davies 1997</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>; <a href="./references#CD002312-bbs2-0012" title="TuncozgurB , UstunsoyH , DikensoyO , TopalM , SanliM , ElbeyliL . Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice2001;55(10):658‐60. ">Tuncozgur 2001</a>). There was no clear difference between the groups for this outcome (OR 1.16, 95% CI 0.71 to 1.91; 867 participants; I² = 0%) (<a href="./references#CD002312-fig-00101" title="">Analysis 1.1</a>; <a href="#CD002312-fig-0005">Figure 5</a>). In a population with a 14% baseline mortality risk (risk taken from the placebo arm of the largest study (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>)), adding intrapleural fibrinolysis to chest tube drainage leads to 19 more deaths per 1000 people (CI 36 fewer to 59 more deaths). However, the confidence intervals in the estimate of the odds ratio are relatively wide and do not exclude clinically significant harm or benefit, reducing our confidence in the estimate of effect. There was no evidence of difference when the sensitivity analysis was restricted to studies at low or unclear risk of bias (OR 1.24, 95% CI 0.74 to 2.07; 4 studies, 598 participants; I² = 0%). </p> <div class="figure" id="CD002312-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.1 Treatment failure‐ death." data-id="CD002312-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.1 Treatment failure‐ death. </p> </div> </div> </div> </section> <section id="CD002312-sec4-0009"> <h5 class="title">Referral for thoracic surgery (open or thorascopic)</h5> <p>Eight studies of fibrinolytics versus placebo reported rate of surgical referral, of which four were at high risk of bias in one or more domains. Both <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a> and <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> had intermediate steps of fibrinolysis when placebo therapy failed prior to referral for surgery; we treated achieving this stage as a referral for surgery in these studies. </p> <p>Meta‐analysis of all included studies showed an odds ratio for fibrinolytic therapy reducing referral for surgery of 0.37 (95% CI 0.21 to 0.68; 8 studies, 897 participants) (<a href="./references#CD002312-fig-00102" title="">Analysis 1.2</a>; <a href="#CD002312-fig-0006">Figure 6</a>). We observed moderate heterogeneity (I² = 51%). However, there was no evidence of significant reduction in referral for surgery when sensitivity analysis was confined to studies at low or unclear risk of bias (OR 0.48, 95% CI 0.18 to 1.25; 4 studies, 599 participants; I² = 58%). </p> <div class="figure" id="CD002312-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.2 Treatment failure‐ surgical intervention." data-id="CD002312-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.2 Treatment failure‐ surgical intervention. </p> </div> </div> </div> <p>Rates of surgical referral vary widely from centre to centre. Assuming a 20% baseline referral rate, fibrinolytics lead to 115 fewer (150 to 55 fewer) surgical referrals per 1000 people. <a href="./full#CD002312-tbl-0001">summary of findings Table for the main comparison</a> gives example absolute effects for other baseline referral rates. </p> </section> <section id="CD002312-sec4-0010"> <h5 class="title">Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </h5> <p>Seven studies of fibrinolytics versus placebo reported sufficient data to either directly state or derive the composite outcome of surgery, death or referral for fibrinolysis. Four studies were at high risk of bias in one or more domains. There was a clear treatment effect of fibrinolysis amongst studies (OR 0.16, 95% CI 0.05 to 0.58; 7 studies, 769 participants; I² = 88%) (<a href="./references#CD002312-fig-00103" title="">Analysis 1.3</a>; <a href="#CD002312-fig-0007">Figure 7</a>). A large amount of heterogeneity was present in both the low‐ and unclear‐risk studies (I² = 71%, P= 0.03), as well as when we analysed all studies (I² = 88%, P &lt; 0.00001). </p> <div class="figure" id="CD002312-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy." data-id="CD002312-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy. </p> </div> </div> </div> <p>Sensitivity analysis limiting the analysis to studies at low or unclear risk of bias did not show a significant reduction in overall treatment failure (OR 0.50, 95% CI 0.13 to 1.96; 3 studies, 500 participants; I² = 73%). </p> <p>Compared with a 27% rate of treatment failure with chest tube drainage alone, use of fibrinolytics leads to 214 fewer overall treatment failures per 1000 (252 fewer to 93 fewer). </p> </section> <section id="CD002312-sec4-0011"> <h5 class="title">Serious adverse events</h5> <p>Of the nine studies reporting adverse events comparing fibrinolytics versus placebo, only three reported the occurrence of serious adverse events (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>; <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>; <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>). These included major bleeding (most common serious adverse event, usually intrapleural), as well as significant chest pain, fever/rash and clinical deterioration. All other studies reported that no adverse events occurred in either group. One study reported a possible excess of serious adverse events in the fibrinolytic group (7% versus 3%, P = 0.08) (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>). Overall, we saw no clear difference in the rate of adverse events between fibrinolysis and placebo (OR 1.28, 95% CI 0.36 to 4.57; 9 studies; 935 participants; I<sup>2</sup> = 33%), but the confidence intervals are broad enough to conceal a modest increase in adverse events with fibrinolysis (<a href="./references#CD002312-fig-00104" title="">Analysis 1.4</a>; <a href="#CD002312-fig-0008">Figure 8</a>). If 30 people per 1000 experience serious adverse events with conservative management alone then 50 (23 to 106) per 1000 will have an adverse event with the addition of fibrinolysis. </p> <div class="figure" id="CD002312-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.4 Significant treatment complications." data-id="CD002312-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.4 Significant treatment complications. </p> </div> </div> </div> </section> <section id="CD002312-sec4-0012"> <h5 class="title">Sensitivity analysis</h5> <p><a href="#CD002312-tbl-0007">Table 1</a> summarises the odds ratios for the various outcomes with fibrinolytics versus placebo, broken down by risk of bias in the included studies. As described above, the benefits of fibrinolytics on the need for surgical intervention and on overall treatment failure disappeared when we excluded from the analysis studies judged to be at high risk of bias in at least one domain or when we confined sensitivity analysis to the two studies with all domains at low risk of bias. Deaths and serious adverse events were reported less frequently in the fibrinolytic arms of studies with at least one domain at high risk of bias, though the analysis of all studies was consistent with that of the low/unclear risk of bias studies for these outcomes. </p> <div class="table" id="CD002312-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for fibrinolysis versus placebo ‒ low versus high versus low/unclear risk of bias</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low Risk of Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low or unclear risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High risk of bias<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.16 (0.71 to 1.91)</p> <p>studies = 8, participants = 867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.24 (0.74 to 2.07) studies = 2, participants = 525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.24 (0.74 to 2.07) studies = 4, participants = 598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.56 (0.10 to 3.41) studies = 4, participants = 269</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for surgical intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.37 (0.21 to 0.68)</p> <p>studies = 8, participants = 897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.76 (0.27 to 2.10); studies = 2, participants = 526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.48 (0.18 to 1.25) studies = 4, participants = 599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.28 (0.15 to 0.51) studies = 4, participants = 298</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall treatment failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.16 (0.05 to 0.58)</p> <p>studies = 7, participants = 769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.21 (0.80 to 1.84) studies = 1, participants = 427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.50 (0.13 to 1.96) studies = 3 participants = 500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.08, (0.02 to 0.37) studies = 4, participants = 269</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.28 (0.36 to 4.57)</p> <p>studies = 9, participants = 935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.74 (0.36 to 8.54) studies = 2, participants = 534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.74 (0.36 to 8.54) studies = 4, participants = 607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.53 (0.07 to 3.91) studies = 5, participants = 328</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> "High risk" studies are those with at least 1 domain rated as at high risk of bias. </p> </div> </div> </section> </section> <section id="CD002312-sec3-0027"> <h4 class="title">Streptokinase versus urokinase</h4> <p>One study compared treatment with urokinase versus streptokinase for complicated parapneumonic effusion and empyema (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>). This study was at overall unclear risk of bias. </p> <section id="CD002312-sec4-0013"> <h5 class="title">Mortality</h5> <p>One death was reported in this study, which was thought to be unrelated to pleural disease (other malignancy). This person had a clear pleural cavity at autopsy and their death was therefore not considered to be a result of treatment failure. No other deaths were recorded in this study. </p> </section> <section id="CD002312-sec4-0014"> <h5 class="title">Referral for thoracic surgery (open or thorascopic)</h5> <p>An odds ratio of surgical intervention for streptokinase versus urokinase was calculated at 1.00 (95% CI 0.13 to 7.72) (<a href="./references#CD002312-fig-00202" title="">Analysis 2.2</a>). </p> </section> <section id="CD002312-sec4-0015"> <h5 class="title">Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </h5> <p>An odds ratio of surgical intervention or death of streptokinase versus urokinase was calculated at 1.00 (95% CI 0.13 to 7.72) (<a href="./references#CD002312-fig-00203" title="">Analysis 2.3</a>). </p> </section> <section id="CD002312-sec4-0016"> <h5 class="title">Serious adverse events</h5> <p>There was a non‐statistically significant excess of adverse events in the streptokinase group (2/25 versus 0/25 in the urokinase group) with an odds ratio of streptokinase versus urokinase of 5.43 (95% CI 0.25 to 118.96) (<a href="./references#CD002312-fig-00204" title="">Analysis 2.4</a>). </p> </section> </section> <section id="CD002312-sec3-0028"> <h4 class="title">Alteplase versus urokinase</h4> <p>One study compared treatment with urokinase versus alteplase at two different doses (10 mg daily and 20 mg daily) for complicated parapneumonic effusion and empyema (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>). This study was at high risk of bias as an excess of adverse events was identified in the 20 mg alteplase arm, which resulted in breaking of the blind and alteration of the protocol with a reduced alteplase dose of 10 mg daily. </p> <section id="CD002312-sec4-0017"> <h5 class="title">Mortality</h5> <p>An odds ratio of death comparing alteplase (combining 10 mg and 20 mg groups) with urokinase at one year was 0.94 (95% CI 0.18 to 4.89) (<a href="./references#CD002312-fig-00301" title="">Analysis 3.1</a>). No deaths were identified during hospitalisation in any group. Of note: all the alteplase deaths were in the 10 mg arm but there are too few people in the study to determine if this is a significant finding. </p> </section> <section id="CD002312-sec4-0018"> <h5 class="title">Referral for thoracic surgery (open or thorascopic)</h5> <p>We calculated an odds ratio of referral for surgical intervention comparing combined alteplase groups with urokinase to be 0.46 (95% CI 0.04 to 5.24) (<a href="./references#CD002312-fig-00302" title="">Analysis 3.2</a>). The single referral for surgery in the alteplase group was in the 10 mg arm. Again, there are insufficient numbers in this study for this comparison to be of significant value. </p> </section> <section id="CD002312-sec4-0019"> <h5 class="title">Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </h5> <p>We calculated an odds ratio of overall treatment failure comparing combined alteplase groups with urokinase to be 3.02 (95% CI 0.89 to 10.27) (<a href="./references#CD002312-fig-00303" title="">Analysis 3.3</a>). This effect, although not statistically significant, is in a different direction from the referral for surgical intervention due to the inclusion of serious bleeding as a treatment failure (5/18 in the 20 mg alteplase arm, 4/33 in the 10 mg alteplase arm at day 6) compared with no serious bleeding in the urokinase arm. Of note: requirement for further fibrinolysis was also included in this outcome (1/33 in the 10 mg alteplase arm, 2/48 in the urokinase arm). </p> </section> <section id="CD002312-sec4-0020"> <h5 class="title">Serious adverse events</h5> <p>We calculated an odds ratio of serious adverse events comparing combined alteplase groups with urokinase to be 5.61 (95% CI 1.16 to 27.11) (<a href="./references#CD002312-fig-00304" title="">Analysis 3.4</a>). This was predominantly due to an excess of bleeding events in the alteplase arms (as above), particularly in the 20 mg alteplase arm. This was recognised during the study, resulting in breaking blinding and alteration to the study protocol. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002312-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002312-sec1-0006"></div> <section id="CD002312-sec2-0011"> <h3 class="title" id="CD002312-sec2-0011">Summary of main results</h3> <p>This review identified 10 randomised controlled trials comparing intrapleural fibrinolysis with placebo and two further trials comparing different fibrinolytic agents (one trial of streptokinase versus urokinase and one trial of alteplase versus urokinase). </p> <p>Fibrinolytic therapy did not substantially alter the risk of death in complicated parapneumonic effusion and empyema compared with placebo, based on moderate‐certainty evidence from eight trials including 867 participants (OR 1.16, 95% CI 0.71 to 1.89). These confidence intervals are wide enough that we cannot exclude a modest but clinically significant increase in mortality with fibrinolytic therapy. Although death was a reported outcome in all studies, only four actually reported that deaths had occurred in the study. Time points of death assessment varied from hospital discharge to three months. There was an overall relatively low rate of death (36/448 in participants in the control group) which is lower than reported estimates of mortality in case series (<a href="./references#CD002312-bbs2-0052" title="FarjahF , SymonsRG , KrishnadasanB , WoodDE , FlumDR . Management of pleural space infections: a population‐based analysis. Journal of Thoracic and Cardiovascular Surgery2007;133(2):346‐51. ">Farjah 2007</a>). The majority of the deaths occurred in <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> which also has the highest mortality rate, approaching other case series estimates. </p> <p>Low‐certainty evidence suggests that, when compared with placebo, fibrinolytic therapies reduce the need for referral for thoracic surgery (OR 0.37, 95% CI 0.21 to 0.68). The use of surgery for empyema varies substantially between centres so the impact of fibrinolysis in terms of absolute numbers of people undergoing thoracic surgery will depend on local thoracic surgery practices. Overall treatment failure (a combined end point of mortality and referral for thoracic surgery or further open‐label fibrinolytic therapy) was reduced by fibrinolytics compared with placebo (OR 0.16, 95% CI 0.05 to 0.58). We consider this to be very low certainty evidence, not least because this is discordant with the findings of <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>, the largest included study and one judged to be of low risk of bias. </p> <p>Three studies — <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>, <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> and <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> — reported that serious adverse events had occurred, with other studies positively reporting no events. <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> had the largest number of significant events, of which the most common was haemorrhage (14/208 in fibrinolytic group versus 6/222 in the control group). We did not detect a clear difference in serious adverse event rates with fibrinolysis compared with placebo (OR 1.70, 95% CI 0.76 to 3.82, low‐certainty evidence). Our analysis is not sufficiently powered to exclude a moderate but clinically important increase in, for example, haemorrhage with fibrinolysis. There is insufficient data to give a precise estimate of the overall risk of significant adverse events (OR 1.70, 95% CI 0.76 to 3.82; 9 studies, 935 participants; I² = 33%), and therefore an increased risk of significant adverse events with fibrinolytics is possible. </p> <p>The comparison of alteplase with urokinase identified an excess of adverse events with alteplase compared to urokinase (OR 5.61, 95% CI 1.16 to 27.11) which was predominantly due to excess bleeding (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>). This is at a much higher rate than seen elsewhere in the review. There is a suggestion of a dose‐dependent relationship in the bleeding rate for <a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a> (5/18 in the 20 mg arm, 4/33 in the 10 mg arm). However, excess rates of bleeding were not seen in either <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> which used 25 mg alteplase daily or <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a> which used 10 mg alteplase twice daily. It is likely that post‐marketing surveillance is needed to confirm or refute the suggestion of excess bleeding with alteplase. </p> <p>The comparison of streptokinase with urokinase did not show any large differences in a small study (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>). It is likely that this study has too few people to make a conclusive determination regarding relative efficacy or safety of these two agents. </p> </section> <section id="CD002312-sec2-0012"> <h3 class="title" id="CD002312-sec2-0012">Overall completeness and applicability of evidence</h3> <p>We believe these studies are likely to be reflective of real‐world patients in practice given significant rates of comorbidity in all study populations as well as relatively consistent inclusion criteria. The results are therefore likely generalisable to standard hospital practice. Our deliberate exclusion of studies involving people with tuberculous effusions means our analyses are not applicable to these individuals. </p> <p>Although multiple different fibrinolytic agents were used (streptokinase, urokinase, alteplase and tPA), there appears to be relative consistency in the effect size throughout the studies. The two direct comparisons were consistent with this, with similar rates of success with urokinase and streptokinase in a small comparison (<a href="./references#CD002312-bbs2-0002" title="BourosD , SchizaS , PatsourakisG , ChalkiadakisG , PanagouP , SiafakasN . Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine1997;155(1):291‐5. ">Bouros 1997</a>); and between alteplase and urokinase (<a href="./references#CD002312-bbs2-0001" title="AlemanC , PorcelJM , AlegreJ , RuizE , BielsaS , AndreuJ , et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung2015;193(6):993‐1000. ">Aleman 2015</a>). </p> <p>The partial cross‐over designs of <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a> and <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> with an intermediate fibrinolysis step in failed placebo therapy may impact upon all outcomes; this is likely to be a small effect, however, given the low number of affected patients. We assessed outcomes either at hospital discharge or at three months, depending on available data. We did not use longer‐term data (e.g. 12‐month data in <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>) as empyema or complicated parapneumonic effusions are unlikely to recur following successful therapy. </p> <p>We have not identified any unpublished studies. However, a significant proportion of the identified research predates mandatory trial registration and we therefore believe it is likely there are unpublished studies. Any potential trials are more likely to be negative and would likely reduce the effect size. The funnel plots are consistent with the existence of unpublished small negative trials, although with fewer than 10 included trials these plots should be treated with caution (<a href="./full#CD002312-fig-0001">Figure 1</a>; <a href="./full#CD002312-fig-0002">Figure 2</a>). </p> <p>It is relatively unlikely that further studies of fibrinolysis alone versus placebo will be published as we note that clinical practice has moved away from fibrinolytic monotherapy and towards dual therapy after the publication of <a href="./references#CD002312-bbs2-0010" title="RahmanNM , MaskellNA , WestA , TeohR , ArnoldA , MackinlayC , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine2011;365(6):518‐26. ">Rahman 2011</a>, which showed a significant reduction in referral for surgery with combined fibrinolytic/DNase. The last RCT of fibrinolysis versus placebo in this population was published in 2012 (<a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a>) and no other fibrinolysis versus placebo studies for pleural infection appear to be in progress. It is likely that a planned much larger study of combination fibrinolytic/DNase will give more definitive evidence for combined therapy (Najib Rahman, private communication). </p> <section id="CD002312-sec3-0029"> <h4 class="title">Certainty of the evidence</h4> <p>We are moderately confident that fibrinolytics do not affect the occurrence of mortality compared with placebo. Certainty for other outcomes (surgery, treatment failure and treatment complications) was low or very low owing to possible publication bias (need for surgery <a href="./full#CD002312-fig-0001">Figure 1</a>; and overall treatment failure <a href="./full#CD002312-fig-0002">Figure 2</a>). In addition, sensitivity analysis removing studies at high risk of bias in at least one domain did not show evidence of significant effect for surgery or treatment failure (<a href="#CD002312-tbl-0007">Table 1</a>). We identified significant heterogeneity in the overall treatment failure analysis (I² = 71%) relating to <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>, which we have discussed above. The risk of treatment complications estimate is imprecise, and whilst the confidence intervals cross unity a clinically significant increase in complications with fibrinolysis is not excluded. </p> <p>Overall, we believe the studies included in the low and unclear risk of bias group are generally of good methodological quality but the issues identified above mean that we are moderately confident of the result of the mortality analysis but less so of the other outcomes. </p> </section> </section> <section id="CD002312-sec2-0013"> <h3 class="title" id="CD002312-sec2-0013">Potential biases in the review process</h3> <p>We believe all published studies have been identified using standard Cochrane search methods. It remains possible, however, that unpublished studies significantly affect the analysis. These concerns apply particularly to the outcome of surgical referral for fibrinolytics versus placebo, where the pooled result shows a benefit — i.e. reduction in the number of referrals to thoracic surgery — whereas the largest more robust study did not show a benefit of fibrinolysis (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>). Much of the literature predates mandatory trial registration, however, and small unpublished studies may therefore exist. There was no obvious correlation between risk of bias in individual included studies and their size. Although a primary outcome of combined death or referral for surgical intervention was published for all included trials, a combination end point is more heterogenous and individual death or referral for surgery endpoints may be more accurate, although this does not include treatment failures referred for intermediate fibrinolysis. </p> <p>Sensitivity analysis restricting the meta‐analysis to studies at low or unclear risk of bias does not show a statistically significant positive effect (OR 0.48, 95% CI 0.18 to 1.25; 4 studies, 599 participants; I² = 58%). This assessment is limited by the relatively small number of studies included in the analysis but there may be a degree of small‐study effect on publication bias, and we have therefore downgraded the strength of the summary of findings for all outcomes for fibrinolysis versus placebo to reflect this possibility. </p> </section> <section id="CD002312-sec2-0014"> <h3 class="title" id="CD002312-sec2-0014">Agreements and disagreements with other studies or reviews</h3> <p>The meta‐analysis of <a href="./references#CD002312-bbs2-0058" title="JandaS , SwistonJ . Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta‐analysis. Chest2012;142(2):401‐11. ">Janda 2012</a> comparing fibrinolysis versus placebo is in broad agreement with this review. This review found a reduction in combination death and requirement for surgery (RR 0.50, 95% CI 0.45 to 0.92) and requirement for surgical intervention alone (RR 0.61, 95% CI 0.45 to 0.82), which is consistent with the analyses in this review. Of note: <a href="./references#CD002312-bbs2-0058" title="JandaS , SwistonJ . Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta‐analysis. Chest2012;142(2):401‐11. ">Janda 2012</a> was highly suspicious of publication bias and small‐study effects in their analysis of requirement for surgery (Egger test P = 0.017), as well as presenting a suspicious funnel plot visual inspection. </p> <p>The meta‐analysis of <a href="./references#CD002312-bbs2-0062" title="NieW , LiuY , YeJ , ShiL , ShaoF , YingK , ZhangR . Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: a meta‐analysis of randomized control trials.. Clinical Respiratory Journal2014;8(3):281‐91. ">Nie 2014</a> included all studies of intrapleural fibrinolysis versus placebo identified in this analysis. However this review additionally included two paediatric studies which do not fit the inclusion criteria of this review (<a href="./references#CD002312-bbs2-0068" title="SinghM , MathewJL , ChandraS , KatariyaS , KumarL . Randomised controlled trial of intrapleural streptokinase in empyema thoracis in children. Acta Paediatrica2004;93(11):1443‐5. ">Singh 2004</a>; <a href="./references#CD002312-bbs2-0071" title="ThomsonAH , HullJ , KumarMR , WallisC , Balfour LynnIM . Randomised controlled trial of intrapleural urokinase in the treatment of childhood empyema. Thorax2002;57(4):343‐7. ">Thomson 2002</a>). Nie and colleagues found a reduction of requirement for surgery (OR 0.24, 95% CI 0.10 to 0.60) with a mortality odds ratio similar to this review (OR 1.16, 95% CI 0.71 to 1.89). Other discordances between this review and <a href="./references#CD002312-bbs2-0062" title="NieW , LiuY , YeJ , ShiL , ShaoF , YingK , ZhangR . Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: a meta‐analysis of randomized control trials.. Clinical Respiratory Journal2014;8(3):281‐91. ">Nie 2014</a> include the treatment of "rescue" fibrinolysis following administration of placebo: in <a href="./references#CD002312-bbs2-0062" title="NieW , LiuY , YeJ , ShiL , ShaoF , YingK , ZhangR . Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: a meta‐analysis of randomized control trials.. Clinical Respiratory Journal2014;8(3):281‐91. ">Nie 2014</a>, those in <a href="./references#CD002312-bbs2-0011" title="ThommiG , ShehanJC , RobisonKL , ChristensenM , BackemeyerLA , McLeayMT . A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine2012;106(5):716‐23. ">Thommi 2012</a> were treated as referrals for surgery but those in <a href="./references#CD002312-bbs2-0003" title="BourosD , SchizaS , TzanakisN , ChalkiadakisG , DrositisJ , SiafakasN . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine1999;159(1):37‐42. BourosD , SchizaSE , DrositisJ , TzanakisN , PapalexatosS , MitrouskaI , et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A65. SchizaS , BourosD , MaltezakisG , DrositisJ , TzanakisN , SiafakasNM . Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal1997;10(Suppl 25):455s. ">Bouros 1999</a> were not. The possible increase found by <a href="./references#CD002312-bbs2-0062" title="NieW , LiuY , YeJ , ShiL , ShaoF , YingK , ZhangR . Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: a meta‐analysis of randomized control trials.. Clinical Respiratory Journal2014;8(3):281‐91. ">Nie 2014</a> in serious adverse event rate (OR 1.92, 95% CI 0.87 to 4.21) is broadly consistent with this review's findings. The authors of <a href="./references#CD002312-bbs2-0062" title="NieW , LiuY , YeJ , ShiL , ShaoF , YingK , ZhangR . Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: a meta‐analysis of randomized control trials.. Clinical Respiratory Journal2014;8(3):281‐91. ">Nie 2014</a> considered there was publication bias in this group of trials by visual assessment of a funnel plot. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002312-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.2 Referral for thoracic surgery (open or thorascopic)." data-id="CD002312-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.2 Referral for thoracic surgery (open or thorascopic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy." data-id="CD002312-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002312-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for 2019 update." data-id="CD002312-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Study flow diagram for 2019 update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.1 Treatment failure‐ death." data-id="CD002312-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.1 Treatment failure‐ death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.2 Treatment failure‐ surgical intervention." data-id="CD002312-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.2 Treatment failure‐ surgical intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy." data-id="CD002312-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.4 Significant treatment complications." data-id="CD002312-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.4 Significant treatment complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinolytic therapy versus placebo, Outcome 1 Mortality." data-id="CD002312-fig-00101" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fibrinolytic therapy versus placebo, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinolytic therapy versus placebo, Outcome 2 Referral for thoracic surgery (open or thorascopic)." data-id="CD002312-fig-00102" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Fibrinolytic therapy versus placebo, Outcome 2 Referral for thoracic surgery (open or thorascopic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinolytic therapy versus placebo, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy." data-id="CD002312-fig-00103" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Fibrinolytic therapy versus placebo, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinolytic therapy versus placebo, Outcome 4 Serious adverse events." data-id="CD002312-fig-00104" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Fibrinolytic therapy versus placebo, Outcome 4 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Streptokinase versus urokinase, Outcome 1 Mortality." data-id="CD002312-fig-00201" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Streptokinase versus urokinase, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Streptokinase versus urokinase, Outcome 2 Referral for thoracic surgery (open or thorascopic)." data-id="CD002312-fig-00202" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Streptokinase versus urokinase, Outcome 2 Referral for thoracic surgery (open or thorascopic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Streptokinase versus urokinase, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy." data-id="CD002312-fig-00203" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Streptokinase versus urokinase, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Streptokinase versus urokinase, Outcome 4 Serious adverse events." data-id="CD002312-fig-00204" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Streptokinase versus urokinase, Outcome 4 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alteplase versus urokinase, Outcome 1 Mortality." data-id="CD002312-fig-00301" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Alteplase versus urokinase, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alteplase versus urokinase, Outcome 2 Referral for thoracic surgery (open or thorascopic)." data-id="CD002312-fig-00302" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Alteplase versus urokinase, Outcome 2 Referral for thoracic surgery (open or thorascopic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00303"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alteplase versus urokinase, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy." data-id="CD002312-fig-00303" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Alteplase versus urokinase, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00303">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002312-fig-00304"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/urn:x-wiley:14651858:media:CD002312:CD002312-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_t/tCD002312-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alteplase versus urokinase, Outcome 4 Serious adverse events." data-id="CD002312-fig-00304" src="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Alteplase versus urokinase, Outcome 4 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-fig-00304">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/media/CDSR/CD002312/image_n/nCD002312-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002312-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fibrinolytics compared to placebo in the treatment of complicated parapneumonic effusions and empyema</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fibrinolytics compared to placebo in the treatment of complicated parapneumonic effusions and empyema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult parapneumonic effusions and empyema<br/> <b>Setting:</b> hospital inpatients<br/> <b>Intervention:</b> fibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality.</p> <p>Follow‐up: range 3 months to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.16<br/> (0.71 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>867<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fibrinolysis does not dramatically alter the risk of death. The confidence intervals are wide so we cannot exclude a modest increase in mortality with fibrinolytics. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/> (104 to 235) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Referral for thoracic surgery.<br/> Follow‐up: range 3 months to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>OR 0.37<br/> (0.21 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>897<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Fibrinolytics probably reduce the rate of surgical intervention for empyema, though the use of surgery varies substantially between centres. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (11 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (50 to 145) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000<br/> (174 to 405) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy.<br/> Follow‐up: range 3 months to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.16<br/> (0.05 to 0.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>769<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fibrinolysis may reduce overall treatment failure, perhaps by reducing need for surgical intervention. This result is potentially unreliable as the effect is not seen once the analysis is confined to studies of low risk of bias. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (18 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.28<br/> (0.36 to 4.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>935<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>8 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Given the broad confidence intervals, we cannot exclude a modest increase in treatment complications (particularly bleeding) with fibrinolysis </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/> (23 to 106) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> 14% Mortality rate taken from the placebo arm of the largest study (<a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>). </p> <p><sup>2</sup> Downgraded by 1 point as 4 of the included studies were deemed at high risk of bias in at least 1 domain. </p> <p><sup>3</sup> Downgraded by 1 point as funnel plots (<a href="./full#CD002312-fig-0001">Figure 1</a>, <a href="./full#CD002312-fig-0002">Figure 2</a>) suggests significant risk of publication bias. </p> <p><sup>4</sup> Decision to operate is dependent on many local factors. Example low, moderate and high surgical risk chosen are consistent with the range seen in included trials and authors' practice. </p> <p><sup>5</sup> Downgraded by 1 point as there is inconsistency between <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a> (the largest study, deemed at low risk of bias) and many of the other studies. </p> <p><sup>6</sup> 27% placebo failure rate taken from <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>. </p> <p><sup>7</sup> 3% significant complication rate taken from placebo arm of <a href="./references#CD002312-bbs2-0007" title="MaskellNA , DaviesCW , NunnAJ , HedleyEL , GleesonFV , MillerR , et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine2005;352(9):865‐74. ">Maskell 2005</a>. </p> <p><sup>8</sup> Downgraded by 1 point as 5 of the included studies were deemed at high risk of bias in at least 1 domain. </p> <p><sup>9</sup> Broad confidence intervals do not rule out a clinically significant increase in treatment complications with fibrinolytics so downgraded 1 point for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fibrinolytics compared to placebo in the treatment of complicated parapneumonic effusions and empyema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002312-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Streptokinase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Streptokinase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult parapneumonic effusions and empyema<br/> <b>Setting:</b> hospital inpatients<br/> <b>Intervention:</b> streptokinase<br/> <b>Comparison:</b> urokinase </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with urokinase</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with streptokinase</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.32<br/> (0.01 to 8.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a single death in the urokinase group which was felt by the study authors to be unrelated to pleural infection. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (0 to 256) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Referral for thoracic surgery (open or thorascopic)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.13 to 7.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (11 to 402) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.13 to 7.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (11 to 402) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 5.43<br/> (0.25 to 118.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Based on 1 small RCT, not otherwise felt to be at high risk of bias. Downgraded 2 points for imprecision as very few events so very broad confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Streptokinase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002312-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Alteplase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Alteplase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult parapneumonic effusions and empyema<br/> <b>Setting:</b> hospital inpatients<br/> <b>Intervention:</b> alteplase<br/> <b>Comparison:</b> urokinase </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with urokinase</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with alteplase</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.94<br/> (0.18 to 4.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/> (12 to 246) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Referral for thoracic surgery (open or thorascopic)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.46<br/> (0.04 to 5.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (2 to 186) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.02<br/> (0.89 to 10.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000<br/> (75 to 483) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 5.61<br/> (1.16 to 27.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Substantially more adverse events in the alteplase group compared with urokinase.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/> (48 to 541) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 1 point as based on 1 small RCT judged at high risk of bias in several domains. Also downgraded 1 point for imprecision ‐ wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Alteplase compared to urokinase in addition to chest drainage in the treatment of adult parapneumonic effusions and empyema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002312-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for fibrinolysis versus placebo ‒ low versus high versus low/unclear risk of bias</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low Risk of Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low or unclear risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High risk of bias<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.16 (0.71 to 1.91)</p> <p>studies = 8, participants = 867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.24 (0.74 to 2.07) studies = 2, participants = 525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.24 (0.74 to 2.07) studies = 4, participants = 598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.56 (0.10 to 3.41) studies = 4, participants = 269</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for surgical intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.37 (0.21 to 0.68)</p> <p>studies = 8, participants = 897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.76 (0.27 to 2.10); studies = 2, participants = 526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.48 (0.18 to 1.25) studies = 4, participants = 599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.28 (0.15 to 0.51) studies = 4, participants = 298</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall treatment failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.16 (0.05 to 0.58)</p> <p>studies = 7, participants = 769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.21 (0.80 to 1.84) studies = 1, participants = 427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.50 (0.13 to 1.96) studies = 3 participants = 500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.08, (0.02 to 0.37) studies = 4, participants = 269</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.28 (0.36 to 4.57)</p> <p>studies = 9, participants = 935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.74 (0.36 to 8.54) studies = 2, participants = 534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.74 (0.36 to 8.54) studies = 4, participants = 607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.53 (0.07 to 3.91) studies = 5, participants = 328</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> "High risk" studies are those with at least 1 domain rated as at high risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for fibrinolysis versus placebo ‒ low versus high versus low/unclear risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/full#CD002312-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002312-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fibrinolytic therapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.71, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Referral for thoracic surgery (open or thorascopic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.21, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.05, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.36, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fibrinolytic therapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002312-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Streptokinase versus urokinase</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Referral for thoracic surgery (open or thorascopic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Streptokinase versus urokinase</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002312-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alteplase versus urokinase</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Referral for thoracic surgery (open or thorascopic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alteplase versus urokinase</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002312.pub4/references#CD002312-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002312.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002312-note-1211">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002312-note-1209">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002312-note-1210">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD002312-note-1208">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002312-note-1207">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002312-note-1206">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002312\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002312\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002312\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002312\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002312\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002312.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002312.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002312.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002312.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002312.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716565329"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002312.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716565333"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002312.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da29f1e629379',t:'MTc0MDcxNjU2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 